Currently eight specialties containing a GLP-1 analogue (glucagon-like peptide 1) are marketed. On the one hand, Ozempic, Trulicity, Victoza, doctor. On the other hand, Wegovy and Saxenda are prescribed only in the second-line treatment of obesity. For products indicated for obesity, the National Agency for the Safety of Medicines and Health Products (ANSM) restricts the conditions of prescription and delivery in order to secure their use in a context of potential misuse. Therefore, the initial prescription must be made by a doctor specializing in endocrinology, diabetology or even competent in nutrition. To be “competent in nutrition”, you must have a diploma of additional specialized studies, cross-disciplinary specialized training or validation of acquired experience in nutrition. Renewals can be carried out by any doctor. Marketed since November 2024, Mounjaro has dual indications in type 2 diabetes and obesity. The ANSM specifies that, whatever the indication, this medicine is subject to the conditions of prescription and delivery of GLP-1 analogues indicated in the treatment of obesity, i.e. an initial prescription reserved for specialists.
Source: National Order of Pharmacists; National Agency for the Safety of Medicines and Health Products.
Health
